{"id":14440,"date":"2011-03-04T15:10:29","date_gmt":"2011-03-04T20:10:29","guid":{"rendered":"http:\/\/asweetlife.org\/?p=14440"},"modified":"2015-12-30T03:28:59","modified_gmt":"2015-12-30T08:28:59","slug":"amylins-type-2-diabetes-drug-bydureon-fails-to-meet-primary-end-point-in-new-study","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=14440","title":{"rendered":"Amylin’s Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point in New Study"},"content":{"rendered":"

\"\"<\/a>Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the top-line results from the DURATION-6 study comparing once weekly BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to Novo Nordisk’s daily Victoza (liraglutide (rDNA origin) injection). Both drugs are members of the class of type 2 diabetes medications known as glucagon-like peptide-1 (GLP-1) receptor agonists.<\/p>\n

The 26-week open-label multicenter clinical study compared A1C levels of type 2 diabetes patients taking BYDUREON (2 mg weekly) to patients taking Victoza administered at the maximum approved dose of 1.8 mg daily. The results showed that patients receiving BYDUREON experienced a reduction in A1c of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.<\/p>\n

Gastrointestinal adverse events occurred more frequently among Victoza patients (nausea reported among 20 percent of patients, vomiting 11 percent, diarrhea 13 percent) compared with BYDUREON patients (nausea 9 percent, vomiting 4 percent, diarrhea 6 percent). Injection site nodule occurred more frequently among BYDUREON users (10 percent) compared with Victoza users (1 percent). There were no major hypoglycemia events in either treatment group.<\/p>\n

The companies said further evaluation of this data set is underway and, when complete, the companies plan to submit the full study results for publication.<\/p>\n","protected":false},"excerpt":{"rendered":"

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the top-line results from the DURATION-6 study comparing once weekly BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to Novo Nordisk’s daily Victoza (liraglutide (rDNA origin) injection). Both drugs are members of the class of type 2 diabetes medications known as glucagon-like peptide-1 (GLP-1) receptor agonists…<\/p>\n","protected":false},"author":131,"featured_media":29405,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1443],"tags":[671],"yoast_head":"\nAmylin's Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point<\/title>\n<meta name=\"description\" content=\"The 26-week open-label multicenter clinical study compared A1C levels of type 2 diabetes patients taking BYDUREON to patients taking Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=14440\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=14440\",\"url\":\"https:\/\/asweetlife.org\/?p=14440\",\"name\":\"Amylin's Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=14440#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=14440#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg\",\"datePublished\":\"2011-03-04T20:10:29+00:00\",\"dateModified\":\"2015-12-30T08:28:59+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The 26-week open-label multicenter clinical study compared A1C levels of type 2 diabetes patients taking BYDUREON to patients taking Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=14440#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=14440\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=14440#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg\",\"width\":185,\"height\":139,\"caption\":\"Amylin Lilly Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=14440#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amylin’s Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point in New Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amylin's Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point","description":"The 26-week open-label multicenter clinical study compared A1C levels of type 2 diabetes patients taking BYDUREON to patients taking Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=14440","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=14440","url":"https:\/\/asweetlife.org\/?p=14440","name":"Amylin's Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=14440#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=14440#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg","datePublished":"2011-03-04T20:10:29+00:00","dateModified":"2015-12-30T08:28:59+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The 26-week open-label multicenter clinical study compared A1C levels of type 2 diabetes patients taking BYDUREON to patients taking Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=14440#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=14440"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=14440#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/03\/Amylin-Lilly-Logo1.jpg","width":185,"height":139,"caption":"Amylin Lilly Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=14440#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Amylin’s Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point in New Study"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/14440"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14440"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/14440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29405"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}